Dean L. Schorno - 22 Dec 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: EVP & Chief Financial Officer
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol: RIGL
Transactions as of: 22 Dec 2025
Net transactions value: +$139,786
Form type: 4
Filing time: 29 Dec 2025, 20:06:30 UTC
Previous filing: 17 Sep 2025
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schorno Dean L	EVP & Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO	/s/ Raymond Furey (Attorney-in-Fact)	29 Dec 2025	0001509688

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RIGL	Common Stock	Options Exercise	$39,740	+1,987	+3.4%	$20.00	59,722	22 Dec 2025	Direct	F1, F2
transaction	RIGL	Common Stock	Options Exercise	$68,873	+2,846	+4.8%	$24.20	62,568	22 Dec 2025	Direct	F1
transaction	RIGL	Common Stock	Options Exercise	$31,173	+1,667	+2.7%	$18.70	64,235	22 Dec 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Employee Stock Option (right to buy)	Options Exercise	$0	-1,987	-12%	$0.000000	14,262	22 Dec 2025	Common Stock	1,987	$20.00	Direct	F1, F3
transaction	RIGL	Employee Stock Option (right to buy)	Options Exercise	$0	-2,846	-14%	$0.000000	17,153	22 Dec 2025	Common Stock	2,846	$24.20	Direct	F1, F4
transaction	RIGL	Employee Stock Option (right to buy)	Options Exercise	$0	-1,667	-13%	$0.000000	10,832	22 Dec 2025	Common Stock	1,667	$18.70	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2	Includes 500 shares of common stock acquired under the Issuer's stock purchase plan.
F3	The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period.
F4	The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period.
F5	The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.